Zenas BioPharma doses first subject in Phase 1 trial of oral IL-17 inhibitor ZB021

Zenas BioPharma

Zenas BioPharma

ZBIO

0.00
  • Zenas Biopharma dosed first subject in a Phase 1 study of ZB021, an oral IL-17AA/AF inhibitor, marking start of human testing for program aimed at autoimmune and inflammatory diseases.
  • Trial will assess safety, tolerability, pharmacokinetics in healthy volunteers, then support a proof-of-concept readout in plaque psoriasis.
  • Single-ascending-dose and multiple-ascending-dose results are scheduled for release by year-end 2026, with psoriasis proof-of-concept data expected in 2027.
  • Development plan targets a potential move from proof-of-concept into registration-directed trials, which could shorten timeline to a pivotal program if early data support the approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130650PRIMZONEFULLFEED9719062) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.